Túlio Pfiffer

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case Series and Literature Review

Karla Sawada Toda, Luciana Kikuchi, Aline Lopes Chagas et al. · Journal of Clinical and Translational Hepatology · 2015 · 51 citations · Full text

Medicine, Oncology, Pathology +17

Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib

Leonardo Gomes da Fonseca, Romualdo Barroso‐Sousa, Afonso da Silva Alves Bento et al. · Medical Oncology · 2014 · 45 citations

Medicine, Hematology, Oncology +13

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

Fernanda Branco, Regiane Saraiva de Souza Melo Alencar, Fernanda Volt et al. · Annals of Hepatology · 2017 · 42 citations · Full text

Medicine, Dermatology, Oncology +17

Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma

Leonardo Gomes da Fonseca, Romualdo Barroso‐Sousa, Afonso da Silva Alves Bento et al. · Molecular and Clinical Oncology · 2015 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17